Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation (0SGC)

Delisted
Want to track 0SGC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0SGC is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China

Globenewswire | 1 week ago
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Zacks | 1 month ago
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon

Globenewswire | 1 month ago

Arbutus Biopharma Corporation Profile

Biotechnology Industry
Healthcare Sector
Lindsay Androski CEO
LSE Exchange
CA03879J1003 ISIN
US Country
44 Employees
- Last Dividend
4 Nov 2010 Last Split
3 Aug 2015 IPO Date

Overview

Arbutus Biopharma Corporation, originally known as Tekmira Pharmaceuticals Corporation until its rebranding in July 2015, is a biopharmaceutical entity involved in the development of innovative treatments for the chronic Hepatitis B virus (HBV) infection primarily within the United States. Headquartered in Warminster, Pennsylvania, Arbutus is dedicated to pioneering new therapeutics that promise a brighter future for individuals battling HBV. Their scientific endeavors extend beyond HBV, venturing into small molecule antiviral medicines aimed at various coronaviruses, including COVID-19, marking their commitment to addressing global viral challenges. Arbutus's strategic alliances with esteemed organizations such as Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc., along with a clinical collaboration with Barinthus Biotherapeutics plc, underscore their prominent role in the biopharmaceutical landscape.

Products and Services

  • Imdusiran (AB-729)
  • A cutting-edge, proprietary RNAi therapeutic that is administered subcutaneously. Imdusiran is targeted at suppressing HBV antigens across the board, including HBsAg, a crucial element in the persistence and replication of the virus in infected individuals. This promising candidate stands at the forefront of Arbutus's HBV pipeline, exemplifying their innovative approach to tackling hepatitis B virus infection.

  • AB-101
  • An oral PD-L1 inhibitor currently under development, AB-101 represents another facet of Arbutus’s therapeutic arsenal against HBV. This novel compound aims to reignite the patient's own HBV-specific immune system, showcasing a unique therapeutic approach by leveraging the body’s inherent defense mechanisms to combat the virus.

  • Small Molecule Antivirals for Coronaviruses
  • In response to the global emergency triggered by the coronavirus pandemic, Arbutus has expanded its research and development to include small molecule antivirals targeting not just HBV but also coronaviruses, including COVID-19. This initiative reflects Arbutus’s flexibility and their commitment to contributing significant solutions to pressing global health crises.

  • Clinical Collaboration with Barinthus Biotherapeutics plc to Evaluate VTP-300
  • The partnership with Barinthus Biotherapeutics plc to assess VTP-300 signifies a strategic collaboration aimed at discovering potent therapeutic options. This-in-progress evaluation underscores the dedication of Arbutus to explore collaborative opportunities that can enhance their product offerings and potentially lead to novel treatment paradigms.

Contact Information

Address: 701 Veterans Circle
Phone: 267 469 0914